H. Pylori Treatment Medications
For treatment-naive H. pylori infection, bismuth quadruple therapy (bismuth, metronidazole, tetracycline, and PPI) for 14 days is the preferred first-line regimen when antibiotic susceptibility is unknown. 1
First-Line Treatment Options
The 2024 ACG guidelines provide three primary first-line regimens based on the most recent evidence and rising antibiotic resistance patterns (now exceeding 30% for clarithromycin, levofloxacin, and metronidazole in North America):
Preferred First-Line Regimen
Bismuth Quadruple Therapy (14 days):
- Bismuth subsalicylate ~300mg four times daily
- Metronidazole 500mg three to four times daily
- Tetracycline 500mg four times daily
- PPI (standard dose) twice daily
This regimen is preferred because it maintains effectiveness even in areas with high dual resistance to clarithromycin and metronidazole 2, 3, 1. The bismuth component helps overcome metronidazole resistance that may exist in vitro 3.
Alternative First-Line Options (When Bismuth Unavailable or Contraindicated)
Rifabutin Triple Therapy (14 days):
- Rifabutin 150mg twice daily or 300mg once daily
- Amoxicillin 1000mg twice daily
- PPI (standard dose) twice daily
This is particularly suitable for patients without penicillin allergy and is reasonable to prescribe without prior sensitivity testing since rifabutin and amoxicillin resistance remain rare 2, 1.
Potassium-Competitive Acid Blocker (P-CAB) Dual Therapy (14 days):
- P-CAB with amoxicillin
- This represents one of the three newly approved options since the 2017 guidelines 4, 1
Non-Preferred First-Line Option
Concomitant Therapy (14 days):
- Clarithromycin 500mg twice daily
- Amoxicillin 1000mg twice daily
- Metronidazole 500mg twice daily
- PPI (standard dose) twice daily
This is appropriate only in areas where bismuth is unavailable AND clarithromycin resistance is documented to be low 3. Given current resistance patterns in North America, this should generally be avoided as empiric therapy 1.
Important Caveat on Traditional Triple Therapy
Clarithromycin-based triple therapy (PPI + clarithromycin + amoxicillin) should be avoided as first-line empiric treatment due to declining eradication rates (now 70-85%) driven by increasing clarithromycin resistance 5, 1. This regimen should only be used if antibiotic susceptibility confirms clarithromycin sensitivity.
Salvage Therapy for Treatment Failures
After First Treatment Failure
"Optimized" Bismuth Quadruple Therapy (14 days) is preferred for patients not previously treated with this regimen 2, 1. The optimization refers to ensuring full 14-day duration and proper dosing.
Rifabutin Triple Therapy (14 days) is the preferred alternative for patients who previously failed optimized bismuth quadruple therapy 1.
After Multiple Failures
Levofloxacin-based regimens should only be used with confirmed antibiotic susceptibility testing:
- Levofloxacin 500mg once daily
- Amoxicillin 1000mg twice daily
- PPI (standard dose) twice daily
- Duration: 10-14 days 2, 3
High-Dose Dual Therapy (14 days):
- Amoxicillin 2-3g daily in 3-4 divided doses
- High-dose PPI (double standard dose) twice daily 2
This represents an emerging option for refractory cases and is considered acceptable by all major guidelines as a salvage option 2, 3.
Critical Dosing Details
Standard PPI doses (taken 30 minutes before meals on empty stomach):
- Pantoprazole 40mg
- Lansoprazole 30mg
- Omeprazole 20mg
- Esomeprazole 20mg
- Rabeprazole 20mg
High-dose PPI means double these standard doses 2.
Key Clinical Pitfalls
Duration matters: All guidelines now recommend 14 days for first-line therapy to maximize eradication success 3, 1. The 7-day regimens previously used have inferior outcomes.
Avoid clarithromycin and levofloxacin empirically: These should only be used when susceptibility is confirmed, given resistance rates exceeding 30% 1.
Sequential and hybrid therapies are not recommended: Despite earlier enthusiasm, these non-bismuth quadruple variations are considered non-ideal options 3.
Antibiotic susceptibility testing is increasingly important: For treatment-experienced patients, testing should guide salvage regimen selection rather than empiric retreatment 2, 1.
Probiotics are unproven: Despite marketing claims, adjunctive probiotics have no established benefit for H. pylori eradication and should be considered experimental 2.